Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where soggetti phrase all words 'IBZM' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 117 riferimenti
Si mostrano 100 riferimenti a partire da 1
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Tauscher, J; Kapur, S
      Choosing the right dose of antipsychotics in schizophrenia - Lessons from neuroimaging studies

      CNS DRUGS
    2. Li, HF; Gildehaus, FJ; Dresel, S; Patt, JT; Shen, MH; Zhu, T; Liu, B; Tang, ZG; Tatsch, K; Hahn, K
      Comparison of in vivo dopamine D2 receptor binding of [I-123]AIBZM and [I-123]IBZM in rat brain

      NUCLEAR MEDICINE AND BIOLOGY
    3. Rodolico, C; Toscano, A; De Luca, G; Mazzeo, A; Di Leo, R; Baldari, S; Girlanda, P; Vita, G
      Peripheral neuropathy as the presenting feature of multiple system atrophy

      CLINICAL AUTONOMIC RESEARCH
    4. Markianos, M; Hatzimanolis, J; Lykouras, L
      Neuroendocrine responsivities of the pituitary dopamine system in male schizophrenic patients during treatment with clozapine, olanzapine, risperidone, sulpiride, or haloperidol

      EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE
    5. Bernardo, M; Parellada, E; Lomena, F; Catafau, AM; Font, M; Gomez, JC; Lopez-Carrero, C; Gutierrez, F; Pavia, J; Salamero, M
      Double-blind olanzapine vs. haloperidol D2 dopamine receptor blockade in schizophrenic patients: a baseline-endpoint [I-123]IBZM SPECT study

      PSYCHIATRY RESEARCH-NEUROIMAGING
    6. Tranquart, F; Saliba, E; Barantin, L; Lanneau, M; Simmer, L; Guilloteau, D; Baulieu, JL
      D2 receptor imaging in neonates using I-123 iodobenzamide brain SPECT

      CLINICAL NUCLEAR MEDICINE
    7. Lavigne, GJ; Soucy, JP; Lobbezoo, F; Manzini, C; Blanchet, PJ; Montplaisir, JY
      Double-blind, crossover, placebo-controlled trial of bromocriptine in patients with sleep bruxism

      CLINICAL NEUROPHARMACOLOGY
    8. Videbaek, C; Toska, K; Friberg, L; Holm, S; Angelo, HR; Knudsen, GM
      In vivo measurement of haloperidol affinity to dopamine D2/D3 receptors by[I-123]IBZM and single photon emission computed tomography

      JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM
    9. Tatsch, K
      Imaging of the dopaminergic system in parkinsonism with SPET

      NUCLEAR MEDICINE COMMUNICATIONS
    10. Parsey, RV; Oquendo, MA; Zea-Ponce, Y; Rodenhiser, J; Kegeles, LS; Pratap, M; Cooper, TB; Van Heertum, R; Mann, JJ; Laruelle, M
      Dopamine D-2 receptor availability and amphetamine-induced dopamine release in unipolar depression

      BIOLOGICAL PSYCHIATRY
    11. Kapur, S; Seeman, P
      Does fast dissociation from the dopamine D-2 receptor explain the action of atypical antipsychotics?: A new hypothesis

      AMERICAN JOURNAL OF PSYCHIATRY
    12. Barnas, C; Quiner, S; Tauscher, J; Hilger, E; Willeit, M; Kufferle, B; Asenbaum, S; Brucke, T; Rao, ML; Kasper, S
      In vivo I-123 IBZM SPECT imaging of striatal dopamine 2 receptor occupancyin schizophrenic patients

      PSYCHOPHARMACOLOGY
    13. Castner, SA; Al-Tikriti, MS; Baldwin, RM; Seibyl, JP; Innis, RB; Goldman-Rakic, PS
      Behavioral changes and [I-123]IBZM equilibrium SPECT measurement of amphetamine-induced dopamine release in rhesus monkeys exposed to subchronic amphetamine

      NEUROPSYCHOPHARMACOLOGY
    14. Videbaek, C; Toska, K; Scheideler, MA; Paulson, OB; Knudsen, GM
      SPECT tracer [I-123]IBZM has similar affinity to dopamine D2 and D3 receptors

      SYNAPSE
    15. Brucke, T; Djamshidian, S; Bencsits, G; Pirker, W; Asenbaum, S; Podreka, I
      SPECT and PET imaging of the dopaminergic system in Parkinson's disease

      JOURNAL OF NEUROLOGY
    16. Laruelle, M
      Imaging synaptic neurotransmission with in vivo binding competition techniques: A critical review

      JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM
    17. Meisenzahl, EM; Dresel, S; Frodl, T; Schmitt, GJE; Preuss, UW; Rossmuller, B; Tatsch, K; Mager, T; Hahn, K; Moller, HJ
      D-2 receptor occupancy under recommended and high doses of olanzapine: an iodine-123-iodobenzamide SPECT study

      JOURNAL OF PSYCHOPHARMACOLOGY
    18. Vesely, C; Kufferle, B; Brucke, T; Kasper, S
      Remission of severe tardive dyskinesia in a schizophrenic patient treated with the atypical antipsychotic substance quetiapine

      INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
    19. Radau, PE; Linke, R; Slomka, PJ; Tatsch, K
      Optimization of automated quantification of I-123-IBZM uptake in the striatum applied to parkinsonism

      JOURNAL OF NUCLEAR MEDICINE
    20. Hilger, E; Kasper, S
      Properties and therapeutic use of atypical antipsychotics: a review

      WIENER KLINISCHE WOCHENSCHRIFT
    21. Hermann, W; Barthel, H; Reuter, M; Georgi, P; Dietrich, J; Wagner, A
      Constellation of findings on nigrostriatal system in case of Hallervorden-Spatz Disease

      NERVENARZT
    22. Heinz, A
      Dopamine hypothesis of schizophrenia. New findings support a traditional theory

      NERVENARZT
    23. Kegeles, LS; Abi-Dargham, A; Zea-Ponce, Y; Rodenhiser-Hill, J; Mann, JJ; Van Heertum, RL; Cooper, TB; Carlsson, A; Laruelle, M
      Modulation of amphetamine-induced striatal dopamine release by ketamine inhumans: Implications for schizophrenia

      BIOLOGICAL PSYCHIATRY
    24. Muller-Vahl, KR; Berding, G; Kolbe, H; Meyer, GJ; Hundeshagen, H; Dengler, R; Knapp, WH; Emrich, HM
      Dopamine D-2 receptor imaging in Gilles de la Tourette syndrome

      ACTA NEUROLOGICA SCANDINAVICA
    25. Bartenstein, P; Grunwald, F; Kuwert, T; Tatsch, K; Sabri, O; Benkert, O; Fahlbusch, R; Grunder, G; Herholz, K; Weiller, C
      Clinical applications of single photon emission tomography in neuromedicine - Part 2: dementia, psychotic disorders, inflammation, trauma

      NUKLEARMEDIZIN-NUCLEAR MEDICINE
    26. Zea-Ponce, Y; Laruelle, M
      Protein precipitation: An expedient procedure for the routine analysis of the plasma metabolites of [I-123]IBZM

      NUCLEAR MEDICINE AND BIOLOGY
    27. Zea-Ponce, Y; Laruelle, M
      Synthesis of [I-123]IBZM: A reliable procedure for routine clinical studies

      NUCLEAR MEDICINE AND BIOLOGY
    28. Kasper, S; Tauscher, J; Kufferle, B; Barnas, C; Pezawas, L; Quiner, S
      Dopamine- and serotonin-receptors in schizophrenia: results of imaging-studies and implications for pharmacotherapy in schizophrenia

      EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE
    29. Raedler, TJ; Knable, MB; Lafargue, T; Urbina, RA; Egan, MF; Pickar, D; Weinberger, DR
      In vivo determination of striatal dopamine D-2 receptor occupancy in patients treated with olanzapine

      PSYCHIATRY RESEARCH-NEUROIMAGING
    30. Klimke, A; Larisch, R; Janz, A; Vosberg, H; Muller-Gartner, HW; Gaebel, W
      Dopamine D-2 receptor binding before and after treatment of major depression measured by [I-123]IBZM SPECT

      PSYCHIATRY RESEARCH-NEUROIMAGING
    31. Nakabeppu, Y; Nakajo, M; Mitsuda, M; Tsuchimochi, S; Tani, A; Osame, M
      Iodine-123 iodobenzofuran (I-123 IBF) SPECT in patients with parkinsonism

      ANNALS OF NUCLEAR MEDICINE
    32. Heinz, A; Saunders, RC; Kolachana, BS; Jones, DW; Gorey, JG; Bachevalier, J; Weinberger, DR
      Striatal dopamine receptors and transporters in monkeys with neonatal temporal limbic damage

      SYNAPSE
    33. Panza, N; Rambaldi, PF; Battista, C; Ambrosio, G; Cascini, GL; Schilliro, F; Mansi, L
      Receptor imaging with In-111-pentreotide and(123)I-methoxybenzamide, and inhibition tests with octreotide and bromocriptine of mixed growth hormone/prolactin-secreting pituitary tumors

      BIOMEDICINE & PHARMACOTHERAPY
    34. Bartenstein, P
      Positron-emission-tomography in neurology and psychiatry: clinical applications

      NERVENHEILKUNDE
    35. Dresel, S; Mager, T; Rossmuller, B; Meisenzahl, E; Hahn, K; Moller, HJ; Tatsch, K
      In vivo effects of olanzapine on striatal dopamine D-2/D-3 receptor binding in schizophrenic patients: an iodine-123 iodobenzamide single-photon emission tomography study

      EUROPEAN JOURNAL OF NUCLEAR MEDICINE
    36. Acton, PD; Pilowsky, LS; Kung, HF; Ell, PJ
      Automatic segmentation of dynamic neuroreceptor single-photon emission tomography images using fuzzy clustering

      EUROPEAN JOURNAL OF NUCLEAR MEDICINE
    37. de Herder, WW; Reijs, AEM; de Swart, J; Kaandorp, Y; Lamberts, SWJ; Krenning, EP; Kwekkeboom, DJ
      Comparison of iodine-123 epidepride and iodine-123 IBZM for dopamine D-2 receptor imaging in clinically non-functioning pituitary macroadenomas and macroprolactinomas

      EUROPEAN JOURNAL OF NUCLEAR MEDICINE
    38. Dresel, SHJ; Kung, MP; Huang, XF; Plossl, K; Hou, C; Meegalla, SK; Patselas, G; Mu, M; Saffer, JR; Kung, HF
      Simultaneous SPECT studies of pre- and postsynaptic dopamine binding sitesin baboons

      JOURNAL OF NUCLEAR MEDICINE
    39. Baulieu, JL; Ribeiro, MJ; Levilion-Prunier, C; Tranquart, F; Chartier, JR; Guilloteau, D; Cottier, JP; Besnard, JC; Pourcelot, L; Autret, A
      Effects of the method of drawing regions of interest on the differential diagnosis of extrapyramidal syndromes using I-123-iodolisuride SPET

      NUCLEAR MEDICINE COMMUNICATIONS
    40. Seeman, P; Tallerico, T
      Rapid release of antipsychotic drugs from dopamine D-2 receptors: An explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine

      AMERICAN JOURNAL OF PSYCHIATRY
    41. Grunder, G; Muller, MJ; Andreas, J; Heydari, N; Wetzel, H; Schlosser, R; Schlegel, S; Nickel, O; Eissner, D; Benkert, O
      Occupancy of striatal D-2-like dopamine receptors after treatment with thesigma ligand EMD 57445, a putative atypical antipsychotic

      PSYCHOPHARMACOLOGY
    42. Tauscher, J; Kufferle, B; Asenbaum, S; Fischer, P; Pezawas, L; Barnas, C; Tauscher-Wisniewski, S; Brucke, T; Kasper, S
      In vivo I-123 IBZM SPECT imaging of striatal dopamine-2 receptor occupancyin schizophrenic patients treated with olanzapine in comparison to clozapine and haloperidol

      PSYCHOPHARMACOLOGY
    43. SEEMAN P; TALLERICO T
      ANTIPSYCHOTIC-DRUGS WHICH ELICIT LITTLE OR NO PARKINSONISM BIND MORE LOOSELY THAN DOPAMINE TO BRAIN D2 RECEPTORS, YET OCCUPY HIGH-LEVELS OFTHESE RECEPTORS

      Molecular psychiatry
    44. WANG TST; MALASPINA D; VANHEERTUM RL
      A SIMPLE METHOD OF PREPARATION FOR [I-I23]-(S)-(-)-IBZM

      Applied radiation and isotopes
    45. HEINZ A; KNABLE MB; COPPOLA R; GOREY JG; JONES DW; LEE KS; WEINBERGER DR
      PSYCHOMOTOR SLOWING, NEGATIVE SYMPTOMS AND DOPAMINE-RECEPTOR AVAILABILITY - AN IBZM SPECT STUDY IN NEUROLEPTIC-TREATED AND DRUG-FREE SCHIZOPHRENIC-PATIENTS

      Schizophrenia research
    46. WENNING GK; DONNEMILLER E; GRANATA R; RICCABONA G; POEWE W
      I-123 BETA-CIT AND I-123 IBZM-SPECT SCANNING IN LEVODOPA-NAIVE PARKINSONS-DISEASE

      Movement disorders
    47. SCHWARZ J; TATSCH K; GASSER T; ARNOLD G; POGARELL O; KUNIG G; OERTEL WH
      I-123 IBZM BINDING COMPARED WITH LONG-TERM CLINICAL FOLLOW-UP IN PATIENTS WITH DE-NOVO PARKINSONISM

      Movement disorders
    48. DRESEL S; TATSCH K; DAHNE I; MAGER T; SCHERER J; HAHN K
      IODINE-123-IODOBENZAMIDE SPECT ASSESSMENT OF DOPAMINE D-2 RECEPTOR OCCUPANCY IN RISPERIDONE-TREATED SCHIZOPHRENIC-PATIENTS

      The Journal of nuclear medicine
    49. HIERHOLZER J; CORDES M; VENZ S; SCHELOSKY L; HARISCH C; RICHTER W; KESKE U; HOSTEN N; MAURER J; POEWE W; FELIX R
      LOSS OF DOPAMINE-D2 RECEPTOR-BINDING SITES IN PARKINSONIAN PLUS SYNDROMES

      The Journal of nuclear medicine
    50. KAPUCU LO; KOC E; GUCUYENER K; ZENCIROGLU A; ATALAY Y; UNLU M; VANROYEN E
      D-2 RECEPTOR IMAGING WITH IODINE-123-IODOBENZAMIDE BRAIN SPECT IN INFANTS WITH HYPOXIC-ISCHEMIC BRAIN INJURY

      The Journal of nuclear medicine
    51. LARISCH R; MEYER W; KLIMKE A; KEHREN F; VOSBERG H; MULLERGARTNER HW
      LEFT-RIGHT ASYMMETRY OF STRIATAL DOPAMINE D-2 RECEPTORS

      Nuclear medicine communications
    52. TIBBO P; SILVERSTONE PH; MCEWAN AJB; SCOTT J; JOSHUA A; GOLBERG K
      A SINGLE-PHOTON EMISSION COMPUTED-TOMOGRAPHY SCAN STUDY OF STRIATAL DOPAMINE D-2 RECEPTOR-BINDING WITH I-123 EPIDEPRIDE IN PATIENTS WITH SCHIZOPHRENIA AND CONTROLS

      Journal of psychiatry & neuroscience
    53. WELZ A; POGARELL O; TATSCH K; SCHWARZ J; CRYSSAGIS K; REICHART B
      SURGERY OF THE THORACIC AORTA USING DEEP HYPOTHERMIC TOTAL CIRCULATORY ARREST - ARE THERE NEUROLOGICAL CONSEQUENCES OTHER THAN FRANK CEREBRAL DEFECTS

      European journal of cardio-thoracic surgery
    54. KNABLE MB; HEINZ A; RAEDLER T; WEINBERGER DR
      EXTRAPYRAMIDAL SIDE-EFFECTS WITH RISPERIDONE AND HALOPERIDOL AT COMPARABLE D2 RECEPTOR OCCUPANCY LEVELS

      PSYCHIATRY RESEARCH-NEUROIMAGING
    55. SCHLOSSER R; SCHLEGEL S; HIEMKE C; NICKEL O; BOCKISCH A; RAO ML; HAHN K
      [I-123] IBZM SPECT IN PATIENTS TREATED WITH TYPICAL AND ATYPICAL NEUROLEPTICS - RELATIONSHIP TO DRUG PLASMA-LEVELS AND EXTRAPYRAMIDAL SIDE-EFFECTS

      PSYCHIATRY RESEARCH-NEUROIMAGING
    56. SCHRODER J; BUBECK B; SILVESTRI S; DEMISCH S; SAUER H
      GENDER DIFFERENCES IN D-2 DOPAMINE-RECEPTOR BINDING IN DRUG-NAIVE PATIENTS WITH SCHIZOPHRENIA - AN [I-123] IODOBENZAMIDE SINGLE-PHOTON EMISSION COMPUTED-TOMOGRAPHY STUDY

      PSYCHIATRY RESEARCH-NEUROIMAGING
    57. LARUELLE M; DSOUZA CD; BALDWIN RM; ABIDARGHAM A; KANES SJ; FINGADO CL; SEIBYL JP; ZOGHBI SS; BOWERS MB; JATLOW P; CHARNEY DS; INNIS RB
      IMAGING D-2 RECEPTOR OCCUPANCY BY ENDOGENOUS DOPAMINE IN HUMANS

      Neuropsychopharmacology
    58. SCHWARZ J; TATSCH K; GASSER T; ARNOLD G; OERTEL WH
      [(123)]IBZM BINDING PREDICTS DOPAMINERGIC RESPONSIVENESS IN PATIENTS WITH PARKINSONISM AND PREVIOUS DOPAMINOMIMETIC THERAPY

      Movement disorders
    59. BECKER G; NAUMANN M; SCHEUBECK M; HOFMANN E; DEIMLING M; LINDNER A; GAHN G; REINERS C; TOYKA KV; REINERS K
      COMPARISON OF TRANSCRANIAL SONOGRAPHY, MAGNETIC-RESONANCE-IMAGING, AND SINGLE-PHOTON EMISSION COMPUTED-TOMOGRAPHY FINDINGS IN IDIOPATHIC SPASMODIC TORTICOLLIS

      Movement disorders
    60. ACTON PD; PILOWSKY LS; COSTA DC; ELL PJ
      MULTIVARIATE CLUSTER-ANALYSIS OF DYNAMIC I-123 IODOBENZAMIDE SPET DOPAMINE D-2 RECEPTOR IMAGES IN SCHIZOPHRENIA

      European journal of nuclear medicine
    61. ACTON PD; PILOWSKY LS; SUCKLING J; BRAMMER MJ; ELL PJ
      REGISTRATION OF DYNAMIC DOPAMINE D-2 RECEPTOR IMAGES USING PRINCIPAL COMPONENT ANALYSIS

      European journal of nuclear medicine
    62. VALLABHAJOSULA S; HIRSCHOWITZ J; MACHAC J
      EFFECT OF HALOPERIDOL DOSE ON IODINE-123-IBZM BRAIN SPECT IMAGING IN SCHIZOPHRENIC-PATIENTS

      The Journal of nuclear medicine
    63. PIRKER W; ASENBAUM S; WENGER S; KORNHUBER J; ANGELBERGER P; DEECKE L; PODREKA I; BRUCKE T
      IODINE-123-EPIDEPRIDE-SPECT - STUDIES IN PARKINSONS-DISEASE, MULTIPLESYSTEM ATROPHY AND HUNTINGTONS-DISEASE

      The Journal of nuclear medicine
    64. ICHISE M; BALLINGER JR; VINES D; TSAI S; KUNG HF
      SIMPLIFIED QUANTIFICATION AND REPRODUCIBILITY STUDIES OF DOPAMINE D2-RECEPTOR BINDING WITH IODINE-123-IBF SPECT IN HEALTHY-SUBJECTS

      The Journal of nuclear medicine
    65. HERTEL A; WEPPNER M; BAAS H; SCHREINER M; MAUL FD; BAUM RP; FISCHER PA; HOR G
      QUANTIFICATION OF IBZM DOPAMINE-RECEPTOR SPET IN DE-NOVO PARKINSON PATIENTS BEFORE AND DURING THERAPY

      Nuclear medicine communications
    66. STAFFEN W; HONDL N; TRINKA E; ZENZMAIER R; LADURNER G
      SPET INVESTIGATIONS IN EXTRAPYRAMIDAL DISEASES USING SPECIFIC LIGANDS

      Nuclear medicine communications
    67. LOBBEZOO F; SOUCY JP; HARTMAN NG; MONTPLAISIR JY; LAVIGNE GJ
      EFFECTS OF THE D2 RECEPTOR AGONIST BROMOCRIPTINE ON SLEEP BRUXISM - REPORT OF 2 SINGLE-PATIENT CLINICAL-TRIALS

      Journal of dental research
    68. OLIVER DW; DORMEHL IC; VANDERSCHYF CJ; NEUMEYER JL; HUGO N; KEEVE R; ROSSOUW NT; MULLERGARTNER HW; CASTAGNOLI N
      EFFECT OF THE HALOPERIDOL TETRAHYDROPYRIDINE METABOLITE UOROPHENYL)-4-OXOBUTYL]-1,2,3,6-TETRAHYDROPYRIDINE ON DOPAMINE-RECEPTOR AND TRANSPORTER BINDING - A NONHUMAN PRIMATE I-123 IODOBENZAMIDE AND 2-BETA-CARBOMETHOXY-3-BETA-(4-IODOPHENYL)TROPANE SINGLE-PHOTON EMISSION COMPUTED TOMOGRAPHIC STUDY

      Arzneimittel-Forschung
    69. KUFFERLE B; TAUSCHER J; ASENBAUM S; VESELY C; PODREKA I; BRUCKE T; KASPER S
      IBZM SPECT IMAGING OF STRIATAL DOPAMINE-2 RECEPTORS IN PSYCHOTIC-PATIENTS TREATED WITH THE NOVEL ANTIPSYCHOTIC SUBSTANCE QUETIAPINE IN COMPARISON TO CLOZAPINE AND HALOPERIDOL

      Psychopharmacology
    70. TAUSCHER J; KUFFERLE B; ASENBAUM S; BRUCKE T; KASPER S
      PREVIOUS TREATMENT AS A CONFOUNDING VARIABLE IN STUDIES WITH NOVEL ANTIPSYCHOTICS - 2 CASES OF HIGH DOPAMINE-2 RECEPTOR OCCUPANCY WITH QUETIAPINE

      Psychopharmacology
    71. BETTIN S; KAMPFER I; SEESE A; SCHAFER A; REUTER M; LOSSNER J; DIETRICH J; WAGNER A; KNAPP WH
      STRIATAL UPTAKE OF X-123-BETA-CIT AND I-1 23 IBZM IN PATIENTS WITH EXTRAPYRAMIDAL SYMPTOMS

      Nuklearmedizin
    72. HENKER C; BIDA B; MARKWARDT J; SCHLAG P
      DIAGNOSTIC-VALUE OF (123)IODINE-IBZM-SCIN TIGRAPHY FOR STAGING OF MALIGNANT MELANOMAS

      Nuklearmedizin
    73. SAJI H; TANAHASHI K; KINOSHITA T; IIDA Y; MAGATA Y; YOKOYAMA A
      SYNTHESIS, IN-VITRO BINDING PROFILE AND BIODISTRIBUTION OF A (125)-LABELED N-BENZYL PYRROLIDINYL BENZAMIDE DERIVATIVE - A POTENTIAL RADIOLIGAND FOR MAPPING DOPAMINE D-2 RECEPTORS

      Nuclear medicine and biology
    74. VANDYCK CH; SEIBYL JP; STUBBS JB; ZOGHBI S; WISNIEWSKI G; BALDWIN RM; ZEAPONCE Y; CHARNEY DS; HOFFER PB; INNIS RB
      HUMAN BIODISTRIBUTION AND DOSIMETRY OF THE SPECT D-2 DOPAMINE-RECEPTOR RADIOLIGAND [I-123] IBF

      Nuclear medicine and biology
    75. PELLEVOISIN C; GUILLOTEAU D; BAULIEU JL; LOCH C; DOGNON AM; MAUCLAIRE L; SACCAVINI JC; BESNARD JC; CHALON S
      IODALISURIDE AND IODOBENZAMIDE, 2 LIGANDS FOR SPECT EXPLORATION OF THE DOPAMINERGIC D2 RECEPTORS - A COMPARATIVE-STUDY

      Synapse
    76. JAUSS M; KRACK P; FRANZ M; KLETT R; BAUER R; GALLHOFER B; DORNDORF W
      IMAGING OF DOPAMINE-RECEPTORS WITH [I-123] IODOBENZAMIDE SINGLE-PHOTON EMISSION-COMPUTED TOMOGRAPHY IN NEUROLEPTIC MALIGNANT SYNDROME

      Movement disorders
    77. ODER W; BRUCKE T; KOLLEGGER H; SPATT J; ASENBAUM S; DEECKE L
      DOPAMINE D2 RECEPTOR-BINDING IS REDUCED IN WILSONS-DISEASE - CORRELATION OF NEUROLOGICAL DEFICITS WITH STRIATAL I-123 IODOBENZAMIDE BINDING

      Journal of neural transmission
    78. VANDERSCHYF CJ; DORMEHL IC; OLIVER DW; HUGO N; KEEVE R; MULLERGARTNER HW; POND SM; CASTAGNOLI N
      LONG-TERM TREATMENT WITH THE TETRAHYDROPYRIDINE ANALOG (HPTP) OF HALOPERIDOL INFLUENCES DOPAMINE LIGAND-BINDING IN BABOON BRAIN - AN [I-123] IODOBENZAMIDE (IBZM) SPECT STUDY

      Molecular brain research
    79. SCHWARZ J; OERTEL WH; TATSCH K
      IODINE-123-IODOBENZAMIDE BINDING IN PARKINSONISM - REDUCTION BY DOPAMINE AGONISTS BUT NOT L-DOPA

      The Journal of nuclear medicine
    80. ICHISE M; BALLINGER JR; GOLAN H; VINES D; LUONG A; TSAI S; KUNG HF
      NONINVASIVE QUANTIFICATION OF DOPAMINE D2 RECEPTORS WITH IODINE-123-IBF SPECT

      The Journal of nuclear medicine
    81. LESLIE WD; ABRAMS DN; GREENBERG CR; HOBSON D
      COMPARISON OF IODINE-123-EPIDEPRIDE AND IODINE-123-IBZM FOR DOPAMINE D2 RECEPTOR IMAGING

      The Journal of nuclear medicine
    82. LOBBEZOO F; SOUCY JP; MONTPLAISIR JY; LAVIGNE GJ
      STRIATAL D2 RECEPTOR-BINDING IN SLEEP BRUXISM - A CONTROLLED-STUDY WITH IODINE-123-IODOBENZAMIDE AND SINGLE-PHOTON-EMISSION COMPUTED-TOMOGRAPHY

      Journal of dental research
    83. STAEDT J; STOPPE G; KOGLER A; RIEMANN H; HAJAK G; RODENBECK A; MAYER G; STEINHOFF BJ; MUNZ DL; EMRICH D; RUTHER E
      [I-123] IBZM SPET ANALYSIS OF DOPAMINE D-2 RECEPTOR OCCUPANCY IN NARCOLEPTIC PATIENTS IN THE COURSE OF TREATMENT

      Biological psychiatry
    84. PICKAR D; SU TP; WEINBERGER DR; COPPOLA R; MALHOTRA AK; KNABLE MB; LEE KS; GOREY J; BARTKO JJ; BREIER A; HSIAO J
      INDIVIDUAL VARIATION IN D-2 DOPAMINE-RECEPTOR OCCUPANCY IN CLOZAPINE-TREATED PATIENTS

      The American journal of psychiatry
    85. SCHLEGEL S; SCHLOSSER R; HIEMKE C; NICKEL O; BOCKISCH A; HAHN K
      PROLACTIN PLASMA-LEVELS AND D-2-DOPAMINE RECEPTOR OCCUPANCY MEASURED WITH IBZM-SPECT

      Psychopharmacology
    86. STAEDT J; STOPPE G; KOGLER A; RIEMANN H; HAJAK G; MUNZ DL; EMRICH D; RUTHER E
      NOCTURNAL MYOCLONUS SYNDROME (PERIODIC MOVEMENTS IN SLEEP) RELATED TOCENTRAL DOPAMINE D2-RECEPTOR ALTERATION

      European archives of psychiatry and clinical neuroscience
    87. SCHLOSSER R; SCHLEGEL S
      D-2-RECEPTOR IMAGING WITH [I-123] IBZM AND SINGLE-PHOTON EMISSION TOMOGRAPHY IN PSYCHIATRY - A SURVEY OF CURRENT STATUS

      Journal of neural transmission
    88. STAEDT J; STOPPE G; KOGLER A; RIEMANN H; HAJAK G; MUNZ DL; EMRICH D; RUTHER E
      SINGLE-PHOTON EMISSION TOMOGRAPHY (SPET) IMAGING OF DOPAMINE D-2 RECEPTORS IN THE COURSE OF DOPAMINE REPLACEMENT THERAPY IN PATIENTS WITH NOCTURNAL MYOCLONUS SYNDROME (NMS)

      Journal of neural transmission
    89. LARUELLE M; ABIDARGHAM A; VANDYCK CH; ROSENBLATT W; ZEAPONCE Y; ZOGHBI SS; BALDWIN RM; CHARNEY DS; HOFFER PB; KUNG HF; INNIS RB
      SPECT IMAGING OF STRIATAL DOPAMINE RELEASE AFTER AMPHETAMINE CHALLENGE

      The Journal of nuclear medicine
    90. BUCK A; WESTERA G; SUTTER M; ALBANI C; KUNG HF; VONSCHULTHESS GK
      IODINE-223-IBF SPECT EVALUATION OF EXTRAPYRAMIDAL DISEASES

      The Journal of nuclear medicine
    91. KNABLE MB; JONES DW; COPPOLA R; HYDE TM; LEE KS; GOREY J; WEINBERGER DR
      LATERALIZED DIFFERENCES IN IODINE-123-IBZM UPTAKE IN THE BASAL GANGLIA IN ASYMMETRIC PARKINSONS-DISEASE

      The Journal of nuclear medicine
    92. NADEAU SE; COUCH MW; DEVANE CL; SHUKLA SS
      REGIONAL-ANALYSIS OF D2 DOPAMINE-RECEPTORS IN PARKINSONS-DISEASE USING SPECT AND IODINE-123-IODOBENZAMIDE

      The Journal of nuclear medicine
    93. REICHE W; GRUNDMANN M; HUBER G
      DOPAMINE D-2-RECEPTOR SPECT WITH [I-123] IODOBENZAMIDE IN THE DIAGNOSIS OF PARKINSONS SYNDROME

      Radiologe
    94. BALDWIN RM; ZEAPONCE Y; ZOGHBI SS; ALTIKRITI MS; SEIBYL JP; SYBIRSKA EH; MALISON RT; LARUELLE M; CHARNEY DS; HOFFER PB; INNIS RB
      PHARMACOKINETICS OF THE 3 RADIOIODINATED DOPAMINE D-2 RECEPTOR LIGANDS [I-123] IBF, [I-123] EPIDEPRIDE AND [I-123] 2'-ISP IN NONHUMAN-PRIMATES

      Nuclear medicine and biology
    95. ALTIKRITI MS; BALDWIN RM; ZEAPONCE Y; SYBIRSKA E; ZOGHBI SS; LARUELLE M; MALISON RT; KUNG HF; KESSLER RM; CHARNEY DS; HOFFER PB; INNIS RB
      COMPARISON OF 3 HIGH-AFFINITY SPECT RADIOTRACERS FOR THE DOPAMINE-D-2RECEPTOR

      Nuclear medicine and biology
    96. VOLK S; MAUL FD; HOR G; SCHREINER M; WEPPNER M; HOLZMANN T; PFLUG B
      DOPAMINE D(2) RECEPTOR OCCUPANCY MEASURED BY SINGLE-PHOTON EMISSION COMPUTED-TOMOGRAPHY WITH I-123 IODOBENZAMIDE IN CHRONIC-SCHIZOPHRENIA

      PSYCHIATRY RESEARCH-NEUROIMAGING
    97. VERMEULEN RJ; DRUKARCH B; VERHOEFF NPLG; GOOSEN C; SAHADAT MCR; WOLTERS EC; VANROYEN EA; STOOF JC
      NO DIRECT CORRELATION BETWEEN BEHAVIORALLY ACTIVE DOSES OF THE DOPAMINE D-2 AGONIST LY-171555 AND DISPLACEMENT OF [I-123] IBZM AS MEASURED WITH SPECT IN MPTP MONKEYS

      Synapse
    98. ZOUAKIA A; CHALON S; KUNG HF; DOGNON AM; SALIBA E; BESNARD JC; GUILLOTEAU D
      RADIOIODINATED TRACERS FOR THE EVALUATION OF DOPAMINE-RECEPTORS IN THE NEONATAL RAT-BRAIN AFTER HYPOXIC-ISCHEMIC INJURY

      European journal of nuclear medicine
    99. LARUELLE M; VANDYCK C; ABIDARGHAM A; ZEAPONCE Y; ZOGHBI SS; CHARNEY DS; BALDWIN RM; HOFFER PB; KUNG HF; INNIS RB
      COMPARTMENTAL MODELING OF IODINE-123-IODOBENZOFURAN BINDING TO DOPAMINE D2 RECEPTORS IN HEALTHY-SUBJECTS

      The Journal of nuclear medicine
    100. HIERHOLZER J; CORDES M; SCHELOSKY L; RICHTER W; KESKE U; VENZ S; SEMMLER W; POEWE W; FELIX R
      DOPAMINE D2 RECEPTOR IMAGING WITH IODINE-123-IODOBENZAMIDE SPECT IN IDIOPATHIC ROTATIONAL TORTICOLLIS

      The Journal of nuclear medicine


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 21/10/19 alle ore 04:08:21